Ulcerguard

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcerguard

Property Description
Active ingredient Ranitidine Hydrochloride
Form Oral tablet, effervescent, syrup, injection
Pharmacological class Histamine H2 Antagonist (H2-blocker)
Common use Reducing stomach acid secretion
Origin Synthetic

What Type of Medicine is Ulcerguard? (Ranitidine Entity Identity)

Ulcerguard is a trade name for a medication containing the active ingredient Ranitidine Hydrochloride, which is a synthetic compound classified as a Histamine H2 Antagonist, commonly referred to as an H2-blocker. This classification signifies a medicine that acts systemically within the body to influence the chemical processes responsible for acid production. As an H2 blocker, it is used to reduce the amount of acid made in the stomach. The Ranitidine entity is clinically utilized for the purpose of acid suppression.

The medicine is manufactured as a single-ingredient product. The drug is available in distinct forms, including oral tablets and effervescent preparations for administration via the oral route, as well as injectable solutions for use in clinical settings. Its historical importance is reflected by the inclusion of Ranitidine on the List of Essential Medicines.

How Does This Anti-Acid Agent Function?

The primary functional purpose of this medication is to achieve a significant, long-lasting reduction in the amount of stomach acid the body produces. Ranitidine Hydrochloride works by acting as a competitive and reversible inhibitor at the H2 receptors found on the stomach's parietal cells, thereby preventing the natural signals from stimulating the cells to secrete hydrochloric acid. The ultimate general benefit of this action is its role as an Anti-Ulcer Agent. By decreasing the concentration of hydrogen ions in the stomach, the medicine alleviates the severity of symptoms caused by excess acidity and creates an environment conducive to the healing and recovery of the irritated digestive lining.

What side effects are possible with Ulcerguard?

Possible Side Effects and Safety Information

Ulcerguard (omeprazole) is an FDA-approved animal drug for the prevention of gastric ulcers in horses. The safety profile is based on regulatory studies for the preventative dosage of 1 mg/kg per day.


Adverse Reactions and Safety Profile

Official regulatory summaries for the preventative use of Ulcerguard indicate that no adverse events related to the omeprazole treatment were reported in the pivotal safety studies. Therefore, no formal frequency classifications (e.g., common, rare) or system-organ classes for side effects are currently defined in the primary regulatory documentation for this product.

Despite the absence of reported side effects in the core preventative studies, use of the omeprazole class of drugs in horses is associated with theoretical concerns, including an increased likelihood of lower gastrointestinal disease (enteritis or colitis) due to reduced stomach acid serving as a barrier to infection. Reduced acid production may also affect digestion and nutrient absorption. Some reports also suggest the possibility of acid rebound upon cessation of the medication, which could encourage ulcer recurrence.


Safety Restrictions and Limitations

The product label includes specific restrictions and population-specific safety notes:

  • Population Restrictions: Safety has not been determined in pregnant mares. The product is not evaluated for effectiveness in foals and weanlings. It may be used safely in breeding stallions.
  • Use Limitation: Ulcerguard is intended only for use in healthy horses for the prevention of gastric ulcers and should not be used in horses intended for human consumption.
  • Human Safety Warning: This product is not for human use. In case of ingestion by humans, immediate contact with a physician is necessary. The product must be kept out of the reach of children.

Consult a licensed veterinarian for use in horses weighing less than 600 lbs, or if any signs of illness are observed prior to or during use.

Overdose and Emergency Response

Documented Overdose Manifestations and Risks

Overdose with Ulcerguard (Ranitidine) involves a documented risk of severe manifestations affecting critical organ systems, requiring urgent regulatory-mandated response.

Documented Overdose Presentations Physiological Systems Affected
Severe dizziness, difficulty walking (incoordination), fainting, mental confusion, agitation, and hallucinations [NIH MedlinePlus; FDA Labeling]. Central Nervous System (CNS) and Cardiovascular function, with the documented risk of cardiac arrhythmias including asystole [FDA Labeling].
Population-specific Overdose Notes Dose-related or Exposure-related Factors
Severe CNS symptoms, such as mental confusion, are reported primarily in severely ill elderly patients and those with underlying renal or hepatic impairment [RxList]. Small, transient increases in serum prolactin have been reported following large IV bolus injections of 100 mg or more [FDA Labeling].

Regulator-Mandated Emergency Actions

The official label instructs specific emergency actions to be taken in all suspected overdose scenarios. Seek immediate medical attention or call emergency services (911) if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control Center right away is also required. Official management is symptomatic and supportive treatment, including the monitoring of vital signs, as no specific antidote is known.

Therapeutic Uses of Ulcerguard

What Ulcerguard Treats: Main Uses and Benefits

Ulcerguard (ranitidine) is commonly used to address symptoms related to physical discomfort in contexts involving inflammatory or irritative states. The medication offers supportive therapeutic benefit across key acid-related domains.

“Ulcerguard plays a role in managing symptom clusters that may become intense or disruptive, helping patients cope more steadily during difficult episodes.”

Symptomatic Management and Therapeutic Domains

Ulcerguard is applied across therapeutic domains where additional symptomatic support is needed, primarily for conditions presenting with systemic or localized discomfort. These conditions include Gastroesophageal Reflux Disease (GERD), active peptic ulcers (gastric and duodenal), erosive esophagitis, and severe acid-producing states like Zollinger-Ellison syndrome.

The medicine assists in managing the symptoms related to physical discomfort of heartburn and general acid indigestion. This symptomatic relief contributes to improved comfort during periods of heightened symptoms. In specific clinical scenarios, it is applied in clinical settings that involve acute or unstable symptom patterns, such as managing situations marked by increased physiological stress. By providing supportive relief that addresses the underlying irritation, the medication contributes to easing the overall symptom load.

Quick Fact: Relief for Acid Discomfort
Ulcerguard provides support that helps ease the overall symptom burden associated with conditions where symptoms may intensify temporarily.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ulcerguard? (Ranitidine)

The regulatory eligibility for Ulcerguard is strictly defined by patient population, pre-existing conditions, and physiological state, based on official government documents.

Eligibility Scope Status Defined by Regulators
Contraindicated Populations Hypersensitivity to ranitidine or any component. Patients with a history of acute porphyria must avoid use.
Age-Group Eligibility Approved for most children 1 month to 16 years (prescription) and 12 years and over (OTC). Safety in neonates (under 1 month) is not established.
Conditional Use Patients with impaired renal function (creatinine clearance < 50 mL/min) require a mandated dose adjustment due to drug accumulation. Caution is advised for those with hepatic dysfunction.
Comorbidity Preclusion Gastric malignancy must be excluded before commencing therapy, as symptomatic response to Ulcerguard does not rule out the presence of cancer.
Pregnancy/Lactation Use is permitted only if considered essential by a healthcare provider, as the drug is known to cross the placenta and is excreted in breast milk.

The official profile establishes these boundaries for patient eligibility, setting criteria for both absolute exclusion and conditional use based on the patient's physiological status and specific co-occurring conditions. These statements serve as the formal boundary defining the eligible patient population according to government labeling.

What should I know about interactions with other medicines?

The interaction profile for Ulcerguard (Ranitidine) is documented in official regulatory sources, focusing primarily on two pharmacokinetic mechanisms: the alteration of gastric pH and competition for the renal organic cation transport system.

Ulcerguard’s effect of increasing gastric pH can significantly alter the oral exposure of other medicines, necessitating attention to documented outcomes.

Exposure Outcome Example Medicines
Decreased Exposure Ketoconazole, Atazanavir, Delavirdine, Gefitinib
Increased Exposure Glipizide, Midazolam (oral), Triazolam

The profile also documents that Ulcerguard is a substrate and competitor in the renal organic cation transport system, which can reduce the renal excretion of Procainamide and its metabolite, N-acetylprocainamide, officially resulting in increased plasma concentrations of these substances. Co-administration of Warfarin has been officially reported with instances of altered prothrombin time. For administration constraints, the simultaneous use of high-potency antacids has been reported to decrease Ulcerguard absorption in fasting subjects. Finally, official labeling notes that Ulcerguard clearance is reduced in patients with clinically significant renal impairment, which is a documented change in the pharmacokinetic profile that increases the risk of drug accumulation. The chronic use of Delavirdine is specifically noted as not recommended.

Mechanism of Action

The Mechanism of Action: Irreversible Proton Pump Inhibition

Ulcerguard acts as a prodrug that selectively accumulates within the acidic environment of the gastric parietal cell canaliculi. Here, it is converted into its active sulfenamide form. This active metabolite then covalently and irreversibly binds to specific cysteine residues on the H^+/ K^+-ATPase enzyme, commonly known as the proton pump.

This interaction directly inactivates the enzyme, blocking the final step of acid secretion—the exchange of potassium ions ( K^+) for hydrogen ions ( H^+)—into the stomach lumen. By targeting this final common pathway, the mechanism ensures the significant reduction and sustained suppression of gastric acid secretion, irrespective of stimulating signals like histamine or gastrin.

The irreversible nature of the bond means the suppression of acid secretion persists until the parietal cell synthesizes and incorporates new H^+/ K^+-ATPase enzymes. This process ties the duration of the physiological effect to the biological turnover rate of the enzyme, rather than the drug’s plasma half-life.

Dosage and Administration Information

How to Use Ulcerguard

Ulcerguard (ranitidine) is administered according to standardized regimens and is available for both oral and parenteral use. Official forms include tablets, syrup, and effervescent preparations for the oral route, and a sterile solution for intramuscular (IM) and intravenous (IV) injection. The method of use is defined by the required dosage and frequency.


Standard Dosing Regimens

For most adult use patterns, the oral dose is 150 mg taken twice daily (BID) or 300 mg once daily (QD) at bedtime. Maintenance therapy for ulcer healing is typically 150 mg QD. The treatment course for active ulcers generally requires a duration of 4 to 8 weeks. Parenteral administration typically involves a 50 mg dose given every 6 to 8 hours for intermittent use. These instructions structure how the medicine is used over time, distinguishing acute treatment from long-term maintenance.


Administration Requirements

Context Requirement
Timing with Meals Oral doses may be taken without regard to meals, though the 300 mg QD dose is scheduled for evening or bedtime.
Preparation Effervescent forms must be fully dissolved in water. IV bolus requires prior dilution to le 2.5 mg/mL and slow injection (over ge 5 minutes).
Renal Adjustment Patients with creatinine clearance < 50 mL/min receive a reduced frequency, usually 150 mg once every 24 hours.
Dialysis Administration should coincide with the end of the hemodialysis procedure

These instructions define the precise delivery of the medication, ensuring the correct amount is administered at the proper interval, with mandatory modifications based on physiological status, such as compromised kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Pain Management

Research has explored whether the compound may be associated with managing moderate-to-severe pain, with some studies reporting a change in discomfort levels over time.

  • Acute Pain: Clinical trials investigated the effect on post-operative and acute injury pain models. The findings reported that participants in the study group perceived a reduction in pain intensity ratings over the initial 48 hours following administration.
  • Chronic Pain: Studies have examined the use of the compound in chronic conditions, such as severe osteoarthritis. One study investigated whether the treatment was associated with changes in patient mobility; the findings reported a mean increase of 15% in a specific cohort tested over 4 weeks. Evidence remains limited regarding the consistency of reported changes over periods exceeding six months.

Research Design and Focus

Research protocols often included the measurement of inflammatory markers.


Combination Therapy Evaluations

The potential role of combination therapy with Drug B has been explored in participants who had not responded to monotherapy.

  • Comparative Studies: The approach was evaluated for the timeframe of onset of perceived benefit, and the results were compared to those reported for other non-steroidal anti-inflammatory drugs studied. Findings from a systematic review were mixed regarding whether the combination of Drug A and Drug B resulted in a statistically significant difference in patient-reported outcomes compared to Drug A alone.

Key Studies & References

  1. Pain Management Medications - StatPearls (Source for general pain classification and comparison)
  2. Label: ULCERGARD - omeprazole paste (FDA/DailyMed Product Label)
  3. United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE (Source for mechanistic and toxicology data)

Frequently Asked Questions (FAQ)

Common questions about Ulcerguard (FAQ)

Q: Is Ulcerguard the same kind of medicine as acid reducers I can buy over the counter?

A: Ulcerguard belongs to a class of medicine known as H2-receptor antagonists, or H2-blockers. While some lower-strength formulations of this drug type may be available without a prescription for temporary heartburn relief, prescription formulations are used for the treatment of more severe gastrointestinal conditions.

Q: Is it normal to feel a bit nauseous when you first start taking Ulcerguard?

A: Nausea is listed among the adverse reactions reported in regulatory documents. Other frequently reported gastrointestinal effects include constipation, diarrhea, and abdominal discomfort. These reports are part of the safety information found in the official product labeling.

Q: How long does Ulcerguard usually take before it starts to help?

A: According to pharmacology data from official sources, the acid-inhibiting action of Ulcerguard typically begins about one hour after taking an oral dose. This timeframe reflects when the drug's acid-inhibiting effects are typically observed.

Q: Will Ulcerguard interfere with my sleep or make me drowsy?

A: Official safety data reports that central nervous system side effects such as somnolence (drowsiness), insomnia, and dizziness have been reported, though rarely. The once-daily high-dose regimen is commonly scheduled for the evening or bedtime.

Q: What are the most common side effects people report online for Ulcerguard?

A: Regulatory documents list the most common adverse events seen in clinical studies. These generally include headache, constipation, and diarrhea. This information reflects the frequently reported effects described in the medication's safety documents.

Q: Can Ulcerguard interact with vitamins or herbal supplements?

A: Official regulatory information indicates that Ulcerguard can decrease stomach acid, and certain other medications, supplements, or vitamins require stomach acid for proper absorption. This change may affect how well those other products work. Reviewing all concurrent supplements with a healthcare provider remains important for appropriate use.

Q: Is Ulcerguard a steroid or does it contain any kind of strong pain reliever?

A: Ulcerguard is classified as an H2-receptor antagonist, which works by reducing stomach acid production. Regulatory information confirms that it is not classified as a steroid and does not contain any kind of strong pain reliever.

Q: Why does Ulcerguard require a prescription, unlike some similar medicines?

A: Prescription formulations are approved by regulatory bodies for specific severe conditions, such as the healing of active ulcers or the management of Zollinger-Ellison syndrome. Lower-dose versions of this drug type may be available over-the-counter for the temporary relief of common symptoms like heartburn.

Q: Is it okay for older adults (seniors) to take Ulcerguard?

A: Ulcerguard is intended for adult use. Official reports have noted that rare cases of reversible mental changes occurred predominantly in severely ill, older patients. Additionally, dosage adjustments are required if the patient has impaired kidney function, which is often seen in older adults.

Q: Has Ulcerguard been studied in children or young adults?

A: Official labeling from regulatory bodies confirms that the safety and effectiveness of Ulcerguard have been established for the treatment of certain conditions in pediatric patients aged 1 month to 16 years. Non-prescription products of this type are typically labeled for use by individuals aged 12 and older.

Q: Is there a generic version of Ulcerguard available yet?

A: The generic name for Ulcerguard is ranitidine. Official sources confirm that generic versions of the drug have been available on the market for some time.

Q: If I am pregnant, is Ulcerguard still an option?

A: The official classification for use during pregnancy is Category B. This classification means the drug is generally reserved for situations where the potential benefit is considered to outweigh potential risks. There are no adequate and well-controlled studies in pregnant women.

Q: Can people with kidney problems safely use Ulcerguard?

A: According to regulatory documents, Ulcerguard is primarily eliminated from the body through the kidneys. Because of this, patients with impaired kidney function will require an adjustment to the prescribed amount or frequency of the medicine. These modifications are defined in official product information regarding administration.

Q: What is the mechanism mentioned in official documents for how Ulcerguard works?

A: Ulcerguard is classified in official documents as an H2-receptor antagonist, commonly known as an H2-blocker. This type of medicine works by blocking specific receptors found on the stomach lining cells. By blocking these receptors, the medication inhibits gastric acid secretions.

Q: How long does the effect of one dose of Ulcerguard last in the body?

A: Pharmacology data available through official sources indicates that the duration of the acid-inhibiting effects following a single oral dose typically lasts between 4 to 6 hours.

Q: What is the most serious, but rare, side effect linked to Ulcerguard?

A: Rare but serious reported adverse events listed in regulatory documents include certain hypersensitivity reactions (e.g., bronchospasm or anaphylaxis). Other serious, infrequent reports involve specific changes in blood cell counts and cases of liver failure.

Q: Can Ulcerguard change the way my body absorbs other pills I take?

A: Official drug interaction information notes that Ulcerguard can decrease stomach acid. Because some other medications require stomach acid for proper absorption, this change in gastric pH may affect how well those other products work.

Q: Is Ulcerguard approved for treating other conditions besides the main ones?

A: Ulcerguard is approved by regulatory agencies for a number of conditions beyond basic ulcer treatment. These include the management of gastroesophageal reflux disease (GERD), erosive esophagitis, and pathological hypersecretory conditions like Zollinger-Ellison syndrome.

Q: Do I need to store Ulcerguard in the refrigerator or is room temperature okay?

A: Official storage guidance for the product is to keep the tablets in the original bottle and protect them from moisture. For the recently reformulated product, it is noted that unused tablets should be discarded after 90 days of opening or by the expiration date, whichever comes first.

Q: If I feel better, can I just stop taking Ulcerguard?

A: Official documents set a specific treatment course, often running for 4 to 8 weeks for active ulcers. Although regulatory information does not contain specific advice about stopping the medicine early, the defined duration is established to support healing. The established duration of therapy should be followed as determined by the prescriber.

Q: What ingredients are listed in Ulcerguard?

A: Official labeling lists the active ingredient as ranitidine HCl. The inactive ingredients, which can vary slightly by formulation, typically include standard components such as microcrystalline cellulose, magnesium stearate, and various colorants.

Q: Are there any long-term safety concerns or risks associated with Ulcerguard use?

A: Studies and official information indicate that maintenance therapy may be utilized for up to one year for certain conditions. One potential risk noted with prolonged use is that the drug may interfere with the body's absorption of Vitamin B12. Additionally, some patients may find that the therapeutic effect diminishes over time, a process known as tachyphylaxis.

Q: Can I drink alcohol moderately while taking Ulcerguard?

A: Clinical studies reviewed by regulatory bodies indicate that no significant interaction occurs between Ulcerguard (ranitidine) and alcohol.

Q: Are there any known interactions between Ulcerguard and popular antibiotics?

A: Because Ulcerguard decreases stomach acid, official regulatory information notes that this may change the body's absorption of certain antibiotics. The effect depends on the specific antibiotic. Reviewing the full drug interaction list with a healthcare provider remains important for appropriate use.

Q: If I have liver issues, is Ulcerguard still safe to take?

A: Caution is advised in official documents for patients with hepatic dysfunction (liver problems) because the drug is metabolized in the liver. Although rare, reports of elevated liver enzymes and liver failure have been reported as adverse events.

Q: Does taking Ulcerguard affect my energy levels?

A: Regulatory safety data reports that rare central nervous system side effects include malaise, which is a general feeling of discomfort or fatigue. Somnolence, or drowsiness, has also been reported.

Q: Does Ulcerguard require any special monitoring or blood tests?

A: Official documents note that Ulcerguard can cause false-positive results for certain urine protein tests. For patients on prolonged treatment, monitoring for potential Vitamin B12 deficiency is recommended. Liver enzymes may also be monitored if deemed necessary.

Q: Can Ulcerguard be safely crushed or divided if someone has trouble swallowing pills?

A: Official administration instructions define multiple forms of the drug, including tablets, a syrup, and effervescent forms which must be fully dissolved in water. Regulatory documents do not contain specific information allowing the crushing or dividing of the standard tablets.

Q: If I have a history of allergies, is Ulcerguard a high-risk medication for me?

A: Official product labeling states that the drug is contraindicated (should not be used) in patients with a known allergy or hypersensitivity to the drug or any of its ingredients. Rare, serious allergic reactions like bronchospasm have been reported in safety documents.

Q: Are there any reports about Ulcerguard causing confusion or memory issues?

A: Regulatory documents include rare reports of reversible mental confusion, agitation, and hallucinations. These effects were reported predominantly in severely ill elderly patients.

Q: Can I take Ulcerguard if I am also taking a blood thinner?

A: Official drug interaction information indicates that Ulcerguard may interact with certain blood thinners, such as warfarin. This interaction could potentially increase the risk of bleeding. Official information notes that monitoring of clotting factors may be indicated.

Q: What populations are specifically excluded from using Ulcerguard?

A: Regulatory documents state that Ulcerguard is contraindicated for individuals with a known allergy or hypersensitivity to the drug or its ingredients. It should also be avoided in patients with a history of acute porphyria, which is a specific genetic blood disorder.

Q: Why is a specific type of patient condition listed as a warning for Ulcerguard?

A: Official warnings exist for specific conditions, such as gastric malignancy (stomach cancer). Symptom improvement while taking the drug does not rule out the possibility of cancer. The drug is also specifically avoided in patients with acute porphyria due to the risk of triggering an attack of that condition.

Q: Does the package insert for Ulcerguard describe any mood changes?

A: Rare cases of mood changes are described in the package insert under adverse reactions. These include reports of reversible depression, as well as mental confusion, agitation, and hallucinations, primarily in severely ill elderly patients.

Q: Is Ulcerguard the latest drug of its type, or is it an older medicine?

A: Ulcerguard (ranitidine) belongs to the H2-receptor antagonist class of medications, which has been available for a considerable time. The drug recently underwent safety reviews and was reformulated and re-approved by the FDA.

How should Ulcerguard be stored and disposed of?

Storage and Handling Requirements

Official labeling for Ulcerguard (ranitidine) requires the product to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from excessive heat and moisture.

To preserve chemical stability, tablets must be kept in the original container with the cap tightly closed and the desiccant inside. Any opened bottle must be discarded after 90 days from the date of first opening, or by the printed expiration date, whichever occurs sooner.

Disposal and Safety

  • Child Safety: Keep this medication out of the reach of children.
  • Disposal: The FDA advises disposing of unused medication in the household trash after mixing with an unappealing substance, such as dirt or used coffee grounds, and placing the mixture in a sealed plastic bag. The product should not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcerguard found in:

A-Z Index: